About Jubilant Pharmova

Jubilant Pharmova Limited operates as an integrated global pharmaceutical and life sciences company. The company manufactures and supplies active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products, and life science ingredients worldwide. The company manufactures and supplies active pharmaceutical ingredients, solid dosage formulations, radiopharmaceuticals, allergy therapy products, advance intermediates, fine ingredients, crop science ingredients, life science chemicals and nutritional products. It also provides services in contract manufacturing of Sterile Injectables and drug discovery solutions. The company offers pharmaceuticals and life sciences products and services across the value chain. It focuses on the pharmaceuticals and life sciences industry. The company serves its customers globally with sales in approximately 100 countries and ground presence in India, North America, Europe and China. Segments The company’s segments include Pharmaceuticals and Life Science Ingredients. Pharmaceuticals This segment includes generics, comprising APIs, solid dosage formulations and India branded pharmaceuticals; and specialty pharmaceuticals (sterile products), comprising radiopharmaceuticals, allergy therapy products, CMO of sterile injectables and drug discovery solutions. The company develops, licenses, manufactures, markets and distributes generics and specialty pharmaceuticals. solid dosage formulations business consists of manufacturing, selling and distribution of its generic formulations. As of March 31, 2016, the company had 51 commercialized products which include over 25 in the US, 9 in Canada, 29 in Europe and 27 in the Rest of the World. Overall the company filed a total of 72 ANDA filings in the US, 90 filings in Europe, 22 filings in Canada and over 650 filings in other countries so far. As on March 31, 2016, the company had received 39 ANDA approvals in the US, 16 approvals in Canada and 86 filings in Europe. The company offers sterile manufacturing services for Phase I through Commercial liquid and lyophilized products in vials and ampoules, as well as ophthalmic and otic solutions. It also offers nonsterile manufacturing services for ointment, cream and liquid products in bottles, tubes, jars, suppositories and applicators. The company develops, manufactures and markets radiopharmaceutical products under Jubilant DraxImage Inc. These products are used in the diagnosis, treatment and monitoring of various diseases. It specializes in cardiac, lung, thyroid, kidney and bone imaging, as well as thyroid disease therapy. The company operates across three functional subsidiaries, such as Jubilant Biosys, Jubilant Chemsys and JDS Malvern which are engaged in discovering new molecules and platforms across therapeutic areas. It collaborates with pharmaceutical & biotechnology companies and academia for preclinical discovery across several disease areas, including Oncology, Metabolic Disorders, Central Nervous System, and Pain & Inflammation. Its focus remains integrated drug discovery programmes -Oncology, Metabolic Disorder, Pain & Inflammation, Central Nervous System. The company focuses on functional services in structural biology, DMPK (drug metabolism and pharmacokinetics), toxicology and chemistry. Life Science Ingredients This segment includes businesses, such as specialty intermediates and nutritional products and life science chemicals. The company’s specialty intermediates business deals in approximately 60 commercial products viz. Pyridines, Picolines, Cyanopyridines and their value added derivatives (Fine Ingredients & Crop Science Ingredients), having applications in pharmaceutical, agrochemical, personal care, and many other life science industries globally. The company’s Specialty Intermediates business deals in approximately than 60 commercial products viz. Pyridines, Picolines, Cyanopyridines and their value added derivatives (Fine Ingredients & Crop Science Ingredients), having applications in pharmaceutical, agrochemical, personal care, and many other life science industries globally. The company primarily manufactures and markets Vitamin B3 (Niacinamide and Niacin) in this segment. Vitamin B3 finds applications in food, animal feed, pharmaceuticals and personal care. It manufactures Vitamin B3 (Niacinamide and Niacin) globally. Business Strategy The company’s core business strategy is its positioning as an integrated global pharmaceutical and life sciences company. The key elements of the company’s strategy are to strength in North America; strong linkages between businesses; deep research and development capabilities; and unique mix of capabilities. Its strategy to grow the top line and continue to be a preferred supplier is based on various strategic imperatives. History The company was founded in 1978. It was formerly known as Vam Organic Chemicals Ltd. and changed its name to Jubilant Organosys Limited in 2001. Further, the company changed its name to Jubilant Life Sciences Limited in 2010 and to Jubilant Pharmova Limited in February 2021.